Rifampin-Resistant TB During Boosted PI Therapy in HIV Patients
In New York City, three HIV patients with tuberculosis developed rifampin resistance after being switched to boosted PI therapy and alternate-day rifabutin.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)